Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses various treatment recommendations for Chronic Prostatitis/Chronic Pelvic Pain Syndrome, noting the need for further trials on herbal therapies and specific indications for surgical intervention, but reports no new clinical results.

This paper discusses risk factors and prevention strategies for acute urinary retention secondary to benign prostatic hyperplasia, emphasizing the role of PSA levels and the benefits of medications like finasteride and alpha-blockers, but reports no new clinical results.

This review highlights that current diagnostic and treatment methods for chronic pelvic pain syndrome lack robust evidence, suggesting a need for further research.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This review discusses the impact of medical and surgical treatments for LUTS/BPH on ejaculatory function, highlighting that most treatments negatively affect it, except for some minimally invasive surgical therapies and specific medical therapies.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

Doxazosin and finasteride negatively affect sexual function in men with BPH.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

In this study, the authors observed that treatment patterns for new benign prostatic hyperplasia largely aligned with guidelines, but 5-α reductase inhibitors were used inappropriately based on prostate size as indicated by prostate specific antigen.

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.

This clinical trial in Poland found that using finasteride, alone or with an alpha-blocker, reduced prostate adenoma size by 40% and improved micturition in patients with benign prostatic hyperplasia.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

This study hypothesizes that the sulfonamide group in tamsulosin might contribute to its association with intraoperative floppy iris syndrome.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

This research concludes that finasteride significantly reduces dihydrotestosterone levels and prostate size in men with BPH and may improve urinary symptoms, with greater baseline prostate size predicting more pronounced benefits compared to placebo.

This research highlights the shift from surgical to pharmacologic and less invasive treatments for benign prostatic hyperplasia, noting finasteride's effectiveness in men with enlarged prostates and its ability to reduce acute urinary retention risk compared to alpha-blockers.

Combining different treatments may be needed to effectively manage chronic prostatitis.

Combining α-blockers and Finasteride is useful for treating small prostate enlargement.

This study found that the epithelial changes in benign prostatic hyperplasia treated with finasteride resembled the pattern of healthy prostates.

This study observed that despite the increase in nocturia cases from 2016 to 2021, the use of pharmacotherapy for the condition declined, suggesting potential undertreatment.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This review discusses the sexual side effects of medical and surgical treatments for benign prostatic hyperplasia, such as erectile dysfunction and changes in ejaculation, but presents no new clinical findings.